Find the Perfect Plan for Your Investment Journey
Last Price
52 Week Range
$84.23 - $157.98
Next Earnings Date
May 07 2025
Next Earnings Date
May 07 2025
Last Price
Market Cap | $10.61B |
EV | $10.03B |
Shares Outstanding | 99.99M |
Beta | 0.33 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $156.37 |
P/E 2025E | 17.61x |
P/Revenue 2025E | 3.99x |
Revenue | 27.60% |
EPS | 49.40% |
Operating Cash Flow | 32.40% |
Free Cash Flow | 33.70% |
Revenue | 14.30% |
EPS | 21.10% |
Operating Cash Flow | 20.30% |
Free Cash Flow | 17.90% |
Gross Margin 2025E | 98.41% |
Net Profit Margin 2025E | 14.98% |
ROE 2025E | 16.56% |
ROCE 2024 | 14.16% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Neurocrine Biosciences, Inc.
NBIX
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Gano, Kyle
Employees
1,800
Website
www.neurocrine.comIPO Date
1996-05-23
Headquarters
12780 El Camino Real, San Diego, California, 92130, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved